טוען...
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk–benefit
Imagine a medicine that is expected to have very limited effects based upon knowledge of its pharmacology and (patho)physiology and that is studied in the wrong population, with low-quality studies that use a surrogate end-point that relates to the clinical end-point in a partial manner at most. Suc...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Blackwell Science Inc
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3690100/ https://ncbi.nlm.nih.gov/pubmed/23216370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12034 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|